MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
IRIDEX Corporation Cost of Revenue 2011-2026 | IRIX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue IRIDEX Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.1 M | 31.6 M | 20.8 M | - | 25.5 M | 25.1 M | 26.1 M | 25.3 M | 21.4 M | - | 19.7 M | 17.5 M | 16.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.6 M | 16.9 M | 23.6 M |
Quarterly Cost of Revenue IRIDEX Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.47 M | 8.89 M | 6.84 M | - | 7.26 M | 7.5 M | 7.3 M | - | 7.23 M | 7.49 M | 7.77 M | - | 8.18 M | 7.49 M | 7.41 M | - | 7.48 M | 7.32 M | 7.02 M | - | 5.15 M | 3.81 M | 5.1 M | - | 6.38 M | 5.88 M | 6.34 M | - | 6.74 M | 6.04 M | 5.59 M | 8.07 M | 6.49 M | 5.51 M | 6.02 M | 6.97 M | 5.54 M | 6.17 M | 6.63 M | - | 4.97 M | 4.82 M | 5.39 M | - | 4.97 M | 5.29 M | 5.27 M | - | 4.8 M | 4.73 M | 4.71 M | - | 3.97 M | 4.33 M | 4.32 M | - | 4.27 M | 4.15 M | 4.11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.89 M | 3.81 M | 6.09 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aethlon Medical
AEMD
|
3.87 M | $ 2.2 | -0.45 % | $ 3.43 M |  USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 10.54 | 0.86 % | $ 1.42 B | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 12.8 | -1.92 % | $ 1.92 B | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 9.78 | -12.37 % | $ 277 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Cognyte Software Ltd.
CGNT
|
104 M | $ 8.37 | 0.12 % | $ 601 M |  Israel |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.04 | -5.28 % | $ 855 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Cytosorbents Corporation
CTSO
|
10.5 M | $ 0.66 | -3.66 % | $ 35.9 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 71.52 | 0.38 % | $ 106 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.86 | -4.93 % | $ 144 M |  France |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.87 | -0.83 % | $ 1.14 B | USA |
 |
Establishment Labs Holdings
ESTA
|
64.8 M | $ 64.93 | -0.12 % | $ 1.92 B |  Costa-rica |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 13.45 | -1.47 % | $ 869 M | Israel |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Abbott Laboratories
ABT
|
19.3 B | $ 107.89 | -2.58 % | $ 188 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 9.45 | -2.98 % | $ 339 M | USA |
 |
Bio-Rad Laboratories
BIO
|
1.19 B | $ 270.01 | 0.23 % | $ 7.62 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.7 | -2.96 % | $ 392 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.1 | -3.46 % | $ 1.28 M | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 31.03 | -5.25 % | $ 1.43 B | USA |
 |
Align Technology
ALGN
|
1.2 B | $ 173.18 | -1.67 % | $ 13 B | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 8.9 | -2.25 % | $ 685 M | USA |
 |
Bruker Corporation
BRKR
|
1.72 B | $ 34.44 | 2.07 % | $ 5.13 K | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Apyx Medical Corporation
APYX
|
19.8 M | $ 3.7 | -1.07 % | $ 152 M | USA |
 |
Second Sight Medical Products
EYES
|
11.8 M | - | -0.97 % | $ 54.4 M | USA |
 |
Accuray Incorporated
ARAY
|
312 M | $ 0.42 | 7.69 % | $ 43.2 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 101.65 | -1.12 % | $ 1.29 B | USA |